Hospital
Artesia General Hospital
Artesia General Hospital was paid $10.26M by Medicaid between Jan 2018 and Dec 2024, across 172 billing codes. Its largest line is 99282, Emergency department visit for the evaluation and management, low to moderate severity — 13% of everything it billed.
33Billing provider infoARTESIA GENERAL HOSPITAL
ARTESIA, NM 88210
ARTESIA, NM 88210
33aNPI1437286044assigned 02/28/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.26M
24GClaims280,059
24DCodes billed172
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#18 of 24
Median peer was paid$20.13M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,780 | $1.48M | |
| 2019 | 30,574 | $961K | |
| 2020 | 22,238 | $793K | |
| 2021 | 30,800 | $997K | |
| 2022 | 43,092 | $1.55M | |
| 2023 | 56,445 | $2.29M | |
| 2024incomplete | 46,130 | $2.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 13% | 14,199 | 13,584 | $1.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 10,416 | 9,856 | $1.19M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.0% | 2,102 | 2,019 | $714K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 4,465 | 4,167 | $658K |
| 80053 | Comprehensive metabolic panel | 4.2% | 19,891 | 17,845 | $427K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 2,454 | 2,304 | $411K |
| 71045 | Radiologic examination, chest; single view | 3.4% | 7,546 | 6,929 | $351K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.4% | 7,333 | 6,513 | $344K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 1,351 | 1,300 | $343K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 5,823 | 1,296 | $341K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.0% | 5,548 | 4,741 | $306K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 3,234 | 2,296 | $284K |
160 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 4,423 | $260K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 5,141 | $187K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 5,651 | $187K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 20,019 | $143K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 906 | $133K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,571 | $133K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 560 | $128K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 3,273 | $120K |
| 87428 | 1.0% | 1,567 | $107K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 240 | $90K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 709 | $88K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,384 | $83K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,906 | $79K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 782 | $77K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,732 | $73K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 461 | $73K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,586 | $71K |
| 84484 | <1% | 4,580 | $66K | |
| 80306 | <1% | 2,521 | $66K | |
| 73630 | <1% | 974 | $60K | |
| 95811 | <1% | 57 | $57K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 709 | $51K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 289 | $51K |
| 73562 | <1% | 593 | $51K | |
| 83880 | <1% | 2,192 | $50K | |
| 80061 | Lipid panel | <1% | 3,521 | $47K |
| 83690 | <1% | 4,778 | $46K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 128 | $44K |
| 81001 | <1% | 9,912 | $43K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,892 | $36K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,855 | $34K |
| 85730 | <1% | 3,953 | $32K | |
| 73610 | <1% | 330 | $29K | |
| 95806 | <1% | 132 | $29K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 986 | $28K |
| 81025 | <1% | 2,549 | $27K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,119 | $26K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 25 | $26K |
| 84439 | <1% | 2,496 | $25K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 277 | $22K |
| 72100 | <1% | 263 | $21K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 497 | $21K |
| 74021 | <1% | 265 | $18K | |
| 73030 | <1% | 215 | $17K | |
| 85610 | <1% | 4,557 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,271 | $16K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 850 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 405 | $16K |
| 73130 | <1% | 219 | $15K | |
| 87186 | <1% | 1,370 | $15K | |
| 84703 | <1% | 1,252 | $15K | |
| 83605 | <1% | 1,025 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 405 | $14K |
| 87430 | <1% | 980 | $14K | |
| 87081 | <1% | 799 | $14K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 140 | $14K |
| 87077 | <1% | 1,569 | $14K | |
| G0378 | Hospital observation service, per hour | <1% | 62 | $13K |
| 84481 | <1% | 718 | $12K | |
| 87040 | <1% | 765 | $11K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 40 | $11K |
| 73110 | <1% | 140 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 708 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 109 | $10K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 527 | $10K |
| 94664 | <1% | 66 | $8K | |
| 82607 | <1% | 513 | $7K | |
| 96376 | <1% | 306 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 52 | $7K |
| 86140 | <1% | 727 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,402 | $6K |
| 87070 | <1% | 618 | $6K | |
| 82550 | <1% | 735 | $5K | |
| 85379 | <1% | 456 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,396 | $5K |
| 74018 | <1% | 81 | $5K | |
| J3490 | Unclassified drugs | <1% | 4,083 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 380 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 41 | $5K |
| 97161 | <1% | 163 | $5K | |
| 86850 | <1% | 555 | $4K | |
| 82553 | <1% | 436 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 70 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,389 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,869 | $4K |
| 82570 | <1% | 521 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 153 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,654 | $4K |
| 82043 | <1% | 502 | $4K | |
| 87400 | <1% | 283 | $4K | |
| 83735 | <1% | 519 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $4K |
| 76641 | <1% | 29 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $3K |
| 82728 | <1% | 248 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,453 | $3K |
| 86900 | <1% | 556 | $3K | |
| 86901 | <1% | 653 | $3K | |
| 85652 | <1% | 784 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 93 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 79 | $3K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 496 | $3K |
| 82150 | <1% | 317 | $3K | |
| 96367 | <1% | 44 | $2K | |
| 82248 | <1% | 330 | $2K | |
| 76942 | <1% | 25 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,101 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 163 | $2K |
| 85027 | <1% | 319 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,762 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 330 | $2K |
| 83540 | <1% | 275 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $1K |
| 76642 | <1% | 13 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,080 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $1K |
| 84466 | <1% | 130 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,451 | $1K |
| 93000 | <1% | 40 | $1K | |
| 82805 | <1% | 16 | $1K | |
| 87420 | <1% | 35 | $1K | |
| 97162 | <1% | 28 | $981.46 | |
| 76536 | <1% | 12 | $948.66 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 31 | $885.25 |
| 81002 | <1% | 279 | $695.87 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,620 | $670.92 |
| 73140 | <1% | 12 | $670.02 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 60 | $645.97 |
| 86703 | <1% | 37 | $564.29 | |
| 73560 | <1% | 13 | $559.21 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 930 | $511.87 |
| 81003 | <1% | 171 | $466.56 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 290 | $461.82 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 506 | $420.14 |
| 84702 | <1% | 14 | $407.57 | |
| 80076 | <1% | 30 | $407.03 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 19 | $373.55 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 25 | $349.36 |
| 80305 | <1% | 25 | $313.79 | |
| 87205 | <1% | 81 | $313.54 | |
| 86141 | <1% | 21 | $296.91 | |
| 88304 | <1% | 15 | $292.62 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 63 | $287.56 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 15 | $267.31 |
| 90714 | <1% | 13 | $264.30 | |
| 97035 | <1% | 24 | $260.66 | |
| 86038 | <1% | 18 | $257.99 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 29 | $241.10 |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 261 | $169.73 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 53 | $161.74 |
| 86592 | <1% | 25 | $155.88 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 54 | $125.21 |
| 86039 | <1% | 14 | $109.01 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 15 | $54.70 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 15 | $45.72 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 31 | $25.60 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 26 | $10.33 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $8.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $7.13 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 24 | $7.07 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSALGADO, JOE (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Artesia General Hospital | Artesia, NM | $4.68M |
| Artesia General Hospital | Artesia, NM | $3.31M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.